Savolitinib

Savolitinib is an oral MET kinase inhibitor jointly developed by AstraZeneca and HUTCHMED, already approved in China as Orpathys for lung cancer driven by MET exon 14 mutations [1] and, more recently, for third-line MET-amplified gastric cancer [12][13]. The Phase 3 story that matters ex-China is SAFFRON (NCT05261399), a 338-patient global trial pairing savolitinib with AstraZeneca's blockbuster osimertinib in EGFR-mutant non-small cell lung cancer patients whose tumors have picked up MET amplification or overexpression as an escape route after progressing on osimertinib alone [4][14]. On August 17, 2026, AstraZeneca reported that SAFFRON hit both progression-free survival (PFS) and overall survival (OS), with statistically significant and clinically meaningful improvements versus platinum-based chemotherapy [14]. This is a direct win at one of the most commercially important resistance mechanisms in lung cancer, since roughly 15 to 25 percent of osimertinib failures involve MET amplification [2]. AstraZeneca now has the dataset to file for ex-China approval and extend the Tagrisso franchise into a defined second-line population. HUTCHMED holds Chinese rights and manufactures the drug; AstraZeneca leads ex-China development. A separate Chinese Phase 3, SACHI (NCT05015608), reported positive PFS at ASCO 2025 and was approved by NMPA in June 2025 for the same setting [3][15].

Savolitinib is not a novel compound. China's NMPA approved it in 2021 as Orpathys for locally advanced or metastatic NSCLC with MET exon 14 skipping alterations, based on a single-arm Phase 2 study [1]. NMPA followed with approval in June 2025 for the pretreated EGFR-mutant, MET-amplified NSCLC combination with osimertinib, based on the SACHI Phase 3 [3][15], and in June 2026 for third-line MET-amplified gastric or GEJ adenocarcinoma [12][13]. Global regulatory status is different. The FDA has not approved savolitinib in any indication, and no breakthrough therapy, fast track, orphan, or accelerated approval designations for the SAFFRON program are publicly documented. The pivotal global trial, SAFFRON (NCT05261399), completed enrollment on October 31, 2025 at 338 patients across 230 centers in 29 countries [4]. On August 17, 2026, AstraZeneca disclosed positive top-line results, statistically significant and clinically meaningful improvements in both PFS and OS versus platinum-based chemotherapy, with a safety profile consistent with prior reports of each agent [14]. Full data are expected at an upcoming oncology congress; regulatory filings (sBLA in the US, MAA in the EU) are the next step but AstraZeneca has not published specific submission timing in the disclosures reviewed here. Supporting data include the ORCHARD Phase 2 biomarker-directed platform study (NCT03944772), which informed dose and combination selection [16], and the SAVANNAH Phase 2, which reported a 49 percent objective response rate in the high MET expression or amplification subset [2]. SAVOIR (NCT03091192) in papillary RCC was truncated at 60 patients due to slow enrollment and shifting standard of care [5]. CALYPSO (savolitinib plus durvalumab in metastatic papillary RCC) reported final results in 2026 [6].

MET is a receptor sitting on the surface of cells that, when it binds a signaling protein called HGF (hepatocyte growth factor), triggers a cascade telling the cell to grow, migrate, and survive. In healthy tissue, this matters for wound healing and organ development. In cancer, MET can get jammed in the 'on' position several ways: mutations in exon 14 that prevent the receptor from being properly turned off, extra copies of the MET gene (amplification), or overproduction of HGF itself. Savolitinib binds MET's kinase domain and shuts off its signaling. The genetic case for hitting MET is strong. Papillary renal cell carcinoma frequently carries MET mutations or amplifications, MET exon 14 alterations define a distinct subset of NSCLC where responses to MET inhibition can be dramatic, and MET-amplified gastric or gastroesophageal cancers show meaningful responses as well [12]. The commercially interesting angle for savolitinib is a different kind of MET biology: acquired resistance. When EGFR-mutant lung cancers treated with osimertinib eventually progress, roughly 15 to 25 percent of those tumors have amplified MET as their escape hatch [2]. Blocking both EGFR (with osimertinib) and MET (with savolitinib) closes that door. Two other MET inhibitors, Novartis's capmatinib and Merck KGaA's tepotinib, are already FDA-approved for METex14 NSCLC, validating the target in the primary-driver setting [7][8].

SAFFRON (NCT05261399) is the global Phase 3 registration trial. It randomized 338 EGFR-mutant, MET-overexpressing or MET-amplified NSCLC patients who had progressed on first- or second-line osimertinib to savolitinib 300 mg twice daily plus osimertinib 80 mg once daily versus platinum-based doublet chemotherapy across 230 centers in 29 countries [4][14]. Primary endpoint was PFS by blinded independent review, with OS as a key secondary endpoint. The comparator is honest: platinum chemo is the actual second-line standard for these patients, not a placebo or a soft comparator. Enrollment completed October 31, 2025 and AstraZeneca reported positive PFS and OS top-line data on August 17, 2026 [14]. The design's main strength is biomarker enrichment. Patients were selected for MET overexpression or amplification, where the mechanistic case is strongest. MET overexpression is detected by immunohistochemistry (IHC), a tissue staining method that measures protein levels; amplification is detected by fluorescence in situ hybridization (FISH) or next-generation sequencing (NGS), which count gene copies directly. Because SAFFRON accepted both readouts as entry criteria, subgroup interpretation across biomarker methods will matter for the label and companion diagnostic. A parallel Chinese Phase 3, SACHI (NCT05015608), enrolled 211 patients between October 2021 and August 2024, hit its PFS primary endpoint at an interim analysis (median PFS 8.2 versus 4.5 months, presented at ASCO 2025), and supported the NMPA approval in June 2025 [3][15]. ORCHARD (NCT03944772), a biomarker-directed Phase 2 platform study, generated the initial combination efficacy and safety signal in osimertinib-progressed patients with MET alterations and informed dose selection for both SACHI and SAFFRON [16]. SAVOIR (NCT03091192) in papillary RCC was truncated at 60 patients when the standard of care shifted toward cabozantinib and immunotherapy combinations, limiting statistical power [5]. CALYPSO in metastatic papillary RCC (savolitinib plus durvalumab) reported final results in 2026 [6].

Our model estimates a 37% chance this drug is eventually approved. It starts from the historical base rate for Phase 3 drugs in this area (about 57%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by its light or open-label blinding and the sponsor's strong record of getting drugs approved; it is held back by weak or limited earlier-phase results and a randomized design. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk is now largely retired given the SAFFRON PFS and OS wins [14], but the shape of the label depends on how the biomarker subgroups played out. SAFFRON used both MET overexpression (IHC) and amplification (FISH or NGS) as entry criteria, and the two populations may not respond identically. If the amplification subgroup drives the signal and the IHC subgroup dilutes it, the FDA may negotiate a narrower label than the trial enrolled. Full congress data will settle this. Safety risk is on-target. MET inhibitors cause peripheral edema, nausea, and hepatic transaminase elevations, and combining with osimertinib layers on interstitial lung disease risk from the EGFR side [10]. The Chinese label carries warnings for both, and AstraZeneca reported no new safety signals in SAFFRON [14]. Regulatory and companion diagnostic risk is meaningful. There is no FDA-approved companion diagnostic for MET amplification in NSCLC. Any US approval will require agreement with the FDA on a specific IHC or FISH cutoff and an approved testing kit, which is a real bottleneck for ex-China commercial rollout. Commercial risk is the bigger question. Even with positive SAFFRON data, the target population is a slice of a slice: EGFR-mutant NSCLC (roughly 15 percent of Western and 40 percent of Asian NSCLC) whose tumors have progressed on osimertinib and specifically developed MET resistance (15 to 25 percent of that progression population). Peak sales in the ex-China market are constrained by that funnel. Capmatinib and tepotinib illustrate the ceiling. Tabrecta generated roughly $200 million in 2023 [17], and analyst estimates put tepotinib in a similar range, well below blockbuster thresholds. Competitive pressure will also come from Johnson & Johnson's amivantamab plus lazertinib and from other EGFR/MET bispecifics moving into post-osimertinib settings.

The catalyst has already fired. SAFFRON's positive PFS and OS top-line on August 17, 2026 [14] moves the story from 'will it read out' to 'what does the label look like and how big is the ex-China commercial opportunity.' The next data points to watch are the full SAFFRON dataset at a major oncology congress (likely ESMO 2026 or an equivalent), the specific hazard ratios and subgroup breakdown by MET IHC versus amplification, and confirmation of the FDA sBLA filing timeline. A hazard ratio measures how the risk of the primary event (in this case disease progression or death) compares between the two arms; a value below 1.0 means the experimental arm had fewer events, and a value around 0.60 means a 40 percent reduction in that risk, a clinically meaningful threshold in this setting. AstraZeneca's 2024 total revenue was $54.1 billion and Tagrisso specifically generated $6.58 billion in 2024 product sales [10], so savolitinib is a small line item in absolute terms but strategically important: it defends the Tagrisso franchise against Johnson & Johnson's amivantamab plus lazertinib and gives AstraZeneca a second-line combination option to keep patients on osimertinib longer. HUTCHMED's outcome is more consequential relative to its size. Orpathys generated only $13.3 million in H1 2026 revenue (largely manufacturing sales to AstraZeneca), against total HUTCHMED oncology revenue of $121 million and full-year 2026 guidance of $330 to $415 million [18]. A successful ex-China launch, plus the recent China gastric cancer approval [12][13], is a meaningful growth axis for HUTCHMED but not a company-transforming one. Worth watching for the congress data and sBLA filing announcement; the surprise-to-the-upside case would be an FDA priority review and a broad biomarker label.